PT-141 blood pressure effects can include a temporary rise in pressure and a slower heart rate after a dose. PT-141 is also called bremelanotide, the ingredient in Vyleesi. That brand's label rules it out for uncontrolled high blood pressure or known heart or blood-vessel disease.
The average changes in studies were small. That doesn't make them harmless for everyone. The starting pressure, heart history, medicines, and actual preparation all matter to the prescribing decision.
PT-141 blood pressure: how much and how long?
The Vyleesi prescribing information on DailyMed reads “Revised: 3/2024.” Section 5.1 describes the following changes in clinical studies:
| Measurement | Reported change | Timing |
|---|---|---|
| Systolic pressure, the upper number | Maximal increase of 6 mmHg | Peak between 2 and 4 hours after a dose |
| Diastolic pressure, the lower number | Maximal increase of 3 mmHg | Peak between 2 and 4 hours after a dose |
| Heart rate | Decrease of up to 5 beats per minute | Accompanies the pressure change |
| Return to starting levels | Pressure and heart rate usually return | Within 12 hours after a dose |
MmHg means millimeters of mercury, the unit on a blood-pressure reading. These figures describe study findings, not a ceiling on one person's possible response. A slower pulse doesn't cancel out a higher pressure reading; they are different measurements.
The full Vyleesi label walkthrough explains the other sections. Here, the important distinction is between a brief peak and an average across several hours. Those numbers can differ without contradicting each other.
Why high blood pressure changes the review
Hypertension means high blood pressure. “Uncontrolled” means it isn't adequately controlled, including when treatment is already prescribed. Section 4 lists uncontrolled hypertension and known cardiovascular disease, meaning disease of the heart or blood vessels, as contraindications: reasons Vyleesi must not be used.
Controlled pressure is a different question, but it doesn't establish eligibility by itself. The label also does not recommend Vyleesi for people at high cardiovascular risk. It calls for assessing that risk before treatment and periodically afterward.
What the monitoring studies actually measured
Ambulatory monitoring means wearing a cuff that records pressure repeatedly during ordinary daily life. It can catch changes a single office reading misses.
Section 12.2 describes 127 women before menopause monitored during daily Vyleesi dosing. After eight days, daytime averages rose by 1.9 mmHg for the upper number and 1.7 for the lower number. Mean peaks were 2.8 mmHg at 4–8 hours for the upper number and 2.7 at 0–4 hours for the lower number. The label reports a mean heart-rate decrease of 0.5 beats per minute and pressure readings similar to starting levels at 12–24 hours.
The FDA's review of that study identifies an important limit. There were 146 women enrolled and 127 who completed the initial treatment period. Only two had controlled hypertension. Everyone knew they received the drug during those first eight days; a later phase compared continued treatment with placebo, an inactive comparison treatment.
That small hypertension subgroup cannot settle the question for everyone taking pressure medicines. Daily dosing here was a study design, not a suggested routine.
An earlier study by White and colleagues, Journal of Hypertension, 2017 assigned 397 women by chance to bremelanotide or placebo. The women had normal or controlled pressure; uncontrolled pressure and recent heart or brain blood-vessel disorders were excluded. Neither participants nor researchers knew the assignments during treatment.
In Table 2 of the full paper, the first 1.75 mg study dose produced average increases above placebo of 3.1 mmHg systolic and 3.2 mmHg diastolic during the first four hours. Heart rate fell by 4.6 beats per minute. These are that study's results, not predictions for another dose or preparation.
What the reviewing provider looks at
Recent readings help establish whether pressure is controlled. The provider considers when and where they were measured, how they vary, and whether treatment recently changed. A single reassuring number doesn't describe the whole pattern.
Heart and blood-vessel history matters separately. A controlled pressure reading doesn't erase an existing diagnosis. The review connects the readings with diagnoses, symptoms, and current care rather than treating each intake answer in isolation.
The medication list includes pressure medicines, other prescriptions, nonprescription medicines, and supplements. Bremelanotide can slow gastric emptying, meaning how quickly the stomach moves its contents onward. That may change absorption of oral medicines. The provider assesses conflicts and coordinates any changes with existing care.
The questions to ask before PT-141 page covers the wider visit. Blood-pressure medicine changes belong to the treating clinician; skipping a medicine is not a workaround for this effect.
Why blood pressure changed the earlier program
Bremelanotide's earlier program used intranasal treatment, meaning delivery through the nose. On August 30, 2007, the sponsors announced that planned phase 3 trials in men were delayed. FDA had questioned the clinical benefit and identified pressure increases as its greatest safety concern. Later development used injection under the skin; White's paper explains that nasal exposure varied widely. PT-141 grew from work on the related tanning peptide melanotan II; who discovered PT-141 follows that history.
Whose evidence is this, and which product?
The two RECONNECT trials enrolled 1,267 women before menopause and evaluated treatment for 24 weeks. The 2019 report by Kingsberg and colleagues in Obstetrics & Gynecology described average pressure rises above placebo of approximately 3 mmHg systolic and 2 mmHg diastolic. The paper's full text states that those changes returned to baseline within 8–10 hours.
The population matters. Vyleesi's indication covers a specific disorder of distressing low desire in women before menopause. The PT-141 evidence for men comes from a different set of studies. The broader PT-141 side-effects guide covers nausea, flushing, and other reactions.
Promise's PT-141 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded means prepared by a pharmacy for an individual prescription. Vyleesi's findings inform the conversation without establishing identical effects for another finished preparation. A licensed provider may still prescribe — that decision is between you and your doctor.
Why an accountable prescription matters
As of October 1, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 named an online seller's PT-141 among unapproved new drugs. The letter addressed that seller's products and marketing. It did not revise Vyleesi's blood-pressure warning.
A prescribed route provides a clinician who reviews heart history, an identifiable licensed dispensing pharmacy, a prescription label, and a contact for problems. Those details make follow-up possible when readings or symptoms change.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, the provider sets the actual dose and monitoring plan. Follow-up checks whether pressure remains controlled and whether the treatment still fits the person's health.
